Blockchain Registration Transaction Record

VolitionRx Achieves 99% Purity Breakthrough in Cancer DNA Detection

VolitionRx announces breakthrough liquid biopsy technology achieving 99% purity in cancer DNA detection, potentially revolutionizing early cancer screening and monitoring with $36B market potential.

This breakthrough represents a potential paradigm shift in cancer diagnostics that could save countless lives through earlier detection. Liquid biopsy technology has long promised a less invasive alternative to traditional tissue biopsies, but the challenge of distinguishing cancer DNA from normal DNA in blood samples has limited its accuracy and clinical utility. VolitionRx's achievement of over 99% purity addresses this fundamental limitation, potentially enabling reliable blood tests for early cancer detection when treatment is most effective. For patients, this could mean earlier diagnosis, better treatment outcomes, and reduced need for invasive procedures. For healthcare systems, it offers the possibility of more accessible, cost-effective screening that could dramatically improve cancer survival rates globally. The technology's applications in both early detection and monitoring treatment response make it particularly valuable in the ongoing fight against cancer, which remains a leading cause of death worldwide.